Park, K., Cho, E. K., Bello, M., Ahn, M. J., Thongprasert, S., Song, E. K., . . . Orlando, M. (2018). Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study.
Chicago Style CitationPark, Keunchil, et al. Efficacy and Safety of First-line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients With Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-label, Randomized SQUIRE Study. 2018.
MLA CitationPark, Keunchil, et al. Efficacy and Safety of First-line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients With Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-label, Randomized SQUIRE Study. 2018.